Objective To systematically evaluate the impact of pulmonary hypertension (PH) on the prognosis of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Methods We conducted a computer-based search of databases including CNKI, WanFang Data, VIP, CBM, PubMed, The Cochrane Library, EMbase and Web of Science from the inception of the databases to June 2023. Two reviewers independently screened articles, extracted data and assessed the quality of the included studies. Meta-analysis was performed using Stata 17.0 software. Results A total of 16 cohort studies with Newcastle-Ottawa Scale score≥7 were included. Meta-analysis results demonstrated that patients with PH who underwent TAVR had significantly higher rates of all-cause mortality at 1 year [OR=2.10, 95%CI (1.60, 2.75), P＜0.01, I2=75%], 30 days [OR=2.09, 95%CI (1.54, 2.83), P＜0.01, I2=33%] and cardiovascular mortality [OR=1.49, 95%CI (1.18, 1.90), P＜0.001, I2=41%], compared to those without PH. There was no statistical difference between the two groups in major bleeding events, stroke, myocardial infarction, pacemaker implantation or postoperative renal failure. Subgroup analysis was conducted for some outcome indicators with significant heterogeneity from the aspects of PH measurement methods, PH diagnostic criteria and different PH types, and the results showed that most outcome indicators were subcombined and the direction was consistent with the overall result, and the heterogeneity was significantly reduced. Conclusion PH can significantly increase the 30 days, 1-year, and cardiovascular mortality rates in severe AS patients undergoing TAVR surgery.